Abstract:Despite the effectiveness of insulin injections in managing hyperglycemia in type 1 diabetes mellitus (T1DM), they fall short in addressing autoimmunity and regenerating damaged islets. This review aims to explore the potential and prospects of emerging treatment modalities for T1DM, including mesenchymal stem cells (MSCs), MSC-derived exosomes, gene therapy, islet allotransplantation, pancreatic islet cell transplantation, and teplizumab. We review emerging treatment modalities for T1DM, highlighting several promising strategies with varied mechanisms and outcomes. Mesenchymal stem cells demonstrate potential in modulating the immune response and preserving or restoring beta-cell function, although variability in sources and administration routes necessitates further standardization. Similarly, MSC-derived exosomes show promise in promoting beta-cell regeneration and immune regulation, supported by early-stage studies showing improved glucose homeostasis in animal models, albeit with limited clinical data. Gene therapy, utilizing techniques like CRISPR-Cas9, offers targeted correction of genetic defects and immune modulation; however, challenges in precise delivery and ensuring long-term safety persist. Islet allotransplantation and pancreatic islet cell transplantation have achieved some success in restoring insulin independence, yet challenges such as donor scarcity and immunosuppression-related complications remain significant. Teplizumab, an anti-CD3 monoclonal antibody, has demonstrated potential in delaying T1DM onset by modulating immune responses and preserving beta-cell function, with clinical trials indicating prolonged insulin production capability. Despite significant progress, standardization, long-term efficacy, and safety continue to pose challenges across these modalities. Conclusion: While these therapies demonstrate significant potential, challenges persist. Future research should prioritize optimizing these treatments and validating them through extensive clinical trials to enhance T1DM management and improve patient outcomes.

Emerging Therapeutics Targeting Cellular Stress Pathways to Mitigate End-Organ Damage in Type 1 Diabetes

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Can We Prevent Mitochondrial Dysfunction and Diabetic Cardiomyopathy in Type 1 Diabetes Mellitus? Pathophysiology and Treatment Options

Exploring Novel Treatment Modalities for Type 1 Diabetes Mellitus: Potential and Prospects

Molecular Mechanism of Islet Β-Cell Functional Alternations During Type 2 Diabetes.

Type 1 diabetes: immune pathology and novel therapeutic approaches

Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes

Β-Cell Dynamics in Type 2 Diabetes and in Dietary and Exercise Interventions

Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents

Latest advancements in the development of new therapies for type 1 diabetes

Current Status on Immunological Therapies for Type 1 Diabetes Mellitus

From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes

Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment

Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes

Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

Inside the β Cell: Molecular Stress Response Pathways in Diabetes Pathogenesis

Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes